M1774, Cemiplimab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squam
Phase 1/2 · Non-Small Cell Lung Cancer |
EMD Serono Research & Development | M1774, Cemiplimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|